<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6</volume><submitter>Xin X</submitter><pubmed_abstract>CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or</pubmed_abstract><journal>Scientific reports</journal><pagination>32804</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5016850</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis.</pubmed_title><pmcid>PMC5016850</pmcid><pubmed_authors>Gu H</pubmed_authors><pubmed_authors>Tan H</pubmed_authors><pubmed_authors>Shi R</pubmed_authors><pubmed_authors>Hua T</pubmed_authors><pubmed_authors>Zeng X</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Xin X</pubmed_authors><pubmed_authors>Jin Z</pubmed_authors><pubmed_authors>Li M</pubmed_authors></additional><is_claimable>false</is_claimable><name>CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis.</name><description>CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Sep</publication><modification>2025-04-21T16:37:33.588Z</modification><creation>2019-03-27T02:23:51Z</creation></dates><accession>S-EPMC5016850</accession><cross_references><pubmed>27608940</pubmed><doi>10.1038/srep32804</doi></cross_references></HashMap>